Basal rapid. The preparations Insuman Rapid GT and Basal GT are insulin, identical in structure to human insulin

Manufacturer– Sanofi-Aventis (France), Sanofi

Name: Insuman® Rapid GT, Insuman® Rapid GT

Compound: 1 ml of neutral solution for injection contains 100 IU of human insulin.
Excipients: m-cresol, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid, water for injection.

Pharmacological action: Insuman Rapid GT contains insulin, which is identical in structure to human insulin and obtained by genetic engineering. The hypoglycemic effect occurs quickly, within 30 minutes, and reaches a maximum within 1-4 hours after subcutaneous administration of the drug. The effect lasts for 7-9 hours. Insuman Rapid GT can be mixed with all human insulins from Hoechst Marion Roussel, with the exception of insulins intended for pump administration.

Indications for use: Insulin-dependent diabetes mellitus. Insuman Rapid GT is indicated for the treatment of diabetic coma and ketoacidosis, as well as for achieving metabolic compensation in patients with diabetes mellitus in the pre-, intra-, and postoperative periods.

Directions for use: Insuman Rapid GT is usually administered deep subcutaneously 15-20 minutes before meals. Intramuscular administration of the drug is allowed. The injection site must be changed every time. Insuman Rapid GT can be administered intravenously in the treatment of hyperglycemic coma and ketoacidosis, as well as to achieve metabolic compensation in the pre-, intra- and postoperative periods in patients with diabetes mellitus. Insuman Rapid GT is not used in various types of insulin pumps (including implanted ones) that use a silicone coating.

Side effects: Sometimes atrophy or hypertrophy of adipose tissue may occur at the injection site, which can be avoided by constantly changing the injection site.

In rare cases, slight redness may occur at the injection site, which disappears with continued therapy. If significant erythema forms, accompanied by itching and swelling, and its rapid spread beyond the injection site, as well as other severe adverse reactions to the components of the drug (insulin, m-cresol), you must immediately inform your doctor about this, since in some cases such reactions can pose a threat to the patient's life.

Severe hypersensitivity reactions are quite rare. They may also be accompanied by the development of angioedema, bronchospasm, a drop in blood pressure and, extremely rarely, anaphylactic shock. Hypersensitivity reactions require immediate correction in insulin therapy and the adoption of appropriate emergency measures.

The formation of antibodies to insulin is possible, which may require adjustment of the dose of insulin administered. Sodium retention with subsequent tissue swelling is also possible, especially after an intensive course of insulin treatment.

Contraindications: Hypersensitivity reaction to insulin or to any of the auxiliary components of the drug, except in cases where insulin therapy is vital. In such cases, the use of Insuman Rapida GT is possible only with careful medical supervision and, if necessary, in combination with antiallergic therapy.

Drug interactions: A weakening of the action of insulin can be observed with the simultaneous administration of insulin and corticotropin, corticosteroids, diazoxide, heparin, isoniazid, barbiturates, nicotinic acid, phenolphthalein, phenothiazine derivatives, phenytoin, diuretics, danazol, doxazosin, glucagon, estrogens and progestogens, somatotropin, sympathomimetic agents and thyroid hubbub. In patients simultaneously receiving insulin and clonidine, reserpine or lithium salts, both weakening and potentiation of the action of insulin may be observed. Pentamidine can cause hypoglycemia followed by hyperglycemia. Drinking alcohol can cause hypoglycemia or lower already low blood sugar levels to dangerous levels. Alcohol tolerance is reduced in patients receiving insulin. Acceptable amounts of alcohol consumed should be determined by a doctor. Chronic alcoholism, as well as chronic overuse of laxatives, can affect glycemic levels. Beta blockers increase the risk of hypoglycemia and, along with other sympatholytic agents (clonidine, guanethidine, reserpine), can weaken or even mask the manifestation of hypoglycemia.

Pregnancy and lactation: Treatment with Insuman Rapid GT should be continued during pregnancy. During pregnancy, especially after the first trimester, you should expect an increase in insulin requirements. However, immediately after delivery, insulin requirements usually decrease, which carries a significant risk of hypoglycemia. During breastfeeding there are no restrictions on insulin therapy. However, dose and diet adjustments may be required.

Storage conditions: Store at temperatures from +2° C to +8° C. Avoid freezing, avoiding direct contact of the bottle with the walls of the freezer compartment or cold storage device.

Additionally: Care should be taken when selecting a dosage regimen for patients with pre-existing ischemic cerebrovascular accidents and severe forms of coronary artery disease. The need for insulin may change when switching to another type of insulin (when replacing insulin of animal origin with Insuman Rapid, the dose is usually reduced), when changing diet, diarrhea, vomiting; changing the usual volume of physical activity, diseases of the kidneys, liver, pituitary gland, thyroid gland, changing the injection site. The patient should be informed about the symptoms of a hypoglycemic state, the first signs of a diabetic coma and the need to inform the doctor about all changes in his condition.

Hypoglycemic drugs are prescribed for diabetes mellitus. Insulin therapy helps regulate blood sugar. Insuman Rapid GT belongs to this group of drugs.

Soluble insulin (human genetically engineered).

ATX

Release forms and composition

The solution is available in bottles or cartridges. Packages with disposable Solostar injector are sold.

The active ingredient in the liquid is human insulin. The concentration of the solution is 3.571 mg, or 100 IU/1 ml.

Pharmacological action

The pharmacological effect is expressed by a decrease in glucose levels. Destructive processes slow down and anabolic effects accelerate. The drug promotes the transport of glucose into the intracellular space, the accumulation of the complex carbohydrate glycogen in muscle tissue and the liver. The removal of pyruvic acid from the body is improved. Against this background, the process of glucose formation from glycogen, as well as from molecules of other organic compounds, slows down.

The mechanism of action is characterized by an increase in the metabolism of glucose into fatty acids and a decrease in the rate of lipolysis.

The distribution of amino acids and potassium in cells and protein metabolism improves.

Pharmacokinetics

When administered subcutaneously, the onset of the effect is observed within half an hour. The maximum effect lasts from 1 to 4 hours. The full duration of the therapeutic effect is from 7 to 9 hours.

Long or short

The active substance is characterized by a short duration of effect.

Indications for use

Cases of drug prescription:

• carrying out insulin therapy;
• the occurrence of complications in diabetes mellitus.

Used on the eve of and during surgical interventions, during the rehabilitation period in order to maintain metabolic compensation.

Contraindications

Contraindications to therapy are hypoglycemia and intolerance to the solution.

Careful use is required in cases such as:

1. Kidney and liver failure.
2. Narrowing of the arteries of the brain and myocardium.
3. Age over 65 years.
4. Proliferative retinopathy.

In case of accidental diseases, the need for insulin may increase, so the use of the drug also requires caution.

How to take Insuman Rapid GT

The solution is intended for intravenous and subcutaneous administration. There are no uniform regulated dosages of the drug. The treatment regimen requires individual adjustment by the attending physician. Different patients have different levels of glucose concentration required to maintain them, so the amount of the drug and the treatment regimen are calculated individually. The attending physician takes into account the patient’s physical activity and dietary habits.

The need to change the amount of the drug may arise in the following cases:

1. When replacing a drug with another type of insulin.
2. When sensitivity to a substance increases due to improved metabolic control.
3. When the patient loses or gains weight.
4. When correcting nutrition, changing the intensity of exercise.

Subcutaneous administration is carried out deeply. It is recommended to carry out the procedure 15 or 20 minutes before meals. It is necessary to change the injection site with each injection. However, depending on the area of ​​administration of the solution, the pharmacokinetics of the drug may change, so changing the area of ​​administration should be agreed with the doctor.

It is necessary to pay attention to the presence of the cap. This indicates the integrity of the bottle. There should be no particles present in the solution, the liquid should be transparent.

The following must be taken into account:

1. When using the solution in a vial, use a suitable plastic syringe.
2. First, air is drawn into the syringe, the amount of which is equal to the dose of the solution. Inject it into the empty space in the bottle. The container is turned over. The solution is being collected. There should be no air bubbles in the syringe. The solution should be slowly injected into the skin fold formed with your fingers.
3. The date on which the first dose of the medicine was taken should be indicated on the label.
4. When using cartridges, it is necessary to use injectors (syringe pens).
5. It is recommended to first leave the cartridge at room temperature for 1 or 2 hours, because the introduction of a cooled substance is painful. Before the injection, any remaining air should be removed.
6. The cartridge cannot be refilled.
7. If the syringe pen is not working, you can use a suitable syringe.

The presence of residues of another drug in the syringe is unacceptable.

Side effects of Insuman Rapid GT

A common side effect is a critical decrease in glucose levels. Most often, the condition develops when the insulin dose is not observed. Repeated episodes provoke the development of neurological disorders. Severe forms of complications, accompanied by convulsions, impaired coordination of movements and coma, are life-threatening for the patient. In these cases, hospitalization is required.

Under the supervision of medical staff, symptoms are relieved by using a concentrated solution of dextrose or glucagon. Important indicators of metabolic status, electrolyte balance and acid-base ratio are collected. The level of glycosylated hemoglobin is monitored.

Phenomena that occur when sugar in the brain substance decreases may be preceded by manifestations of reflex activation of part of the autonomic nervous system. A sharp decrease in blood glucose levels can affect potassium concentrations, causing hypokalemia and cerebral edema.

Blood pressure may decrease.

From the organs of vision

Severe fluctuations in glycemic control can lead to temporary tension in the cell membrane of the eye's lenses and a change in the refractive index. A sharp change in indicators due to an increase in the intensity of therapy may be accompanied by a temporary deterioration in the condition of retinopathy.

In case of severe hypoglycemia against the background of proliferative retinopathy, transient damage to the retina or optic nerve is possible.

Blood-forming organs

Sometimes, during treatment, antibodies to the substance may begin to be produced. In this case, adjustment of the dosage of the drug is necessary.

From the skin

At the site of injection of the solution, pathologies of adipose tissue may develop and local absorption of the substance may decrease.

The injection area may experience itching, pain, redness, hives, swelling or inflammation.

Metabolism

Possible disturbances in sodium metabolism, its retention in the body and the appearance of edema.

Allergies

Skin reactions, bronchospasm, angioedema or anaphylactic shock may occur.

Impact on the ability to operate machinery

Complications of therapy can lead to impaired concentration and decreased reaction speed. This can be dangerous when operating machinery and vehicles.

Special instructions

Cannot be used in pumps with silicone tubes.

Use in old age

In patients over 65 years of age, kidney function decreases. This entails a decrease in the required amount of insulin.

Prescription for children

When treating children, careful selection of dosage is carried out, because insulin requirements are lower than in adults. To prevent the development of severe hyperglycemia, glucose levels are monitored.

Use during pregnancy and lactation

During pregnancy and after childbirth, treatment is not stopped. Adjustments to the treatment regimen and dosage may be necessary due to changes in insulin needs.

Use for renal impairment

As a result of a reduction in metabolic processes with insulin in the body, the need for this substance decreases.

Use for liver dysfunction

The ability to synthesize glucose from non-carbohydrate formations decreases. This may reduce the need for the substance.

Overdose of Insuman Rapid GT

Administration of doses exceeding the body's need for insulin leads to the development of hypoglycemia.

Interaction with other drugs

Contraindicated combinations

The combination of the drug with animal insulin and analogues is excluded.

Joint use of Pentamidine leads to the development of complications.

The following substances and drugs weaken the hypoglycemic effect:

• corticosteroids;
• adrenocorticotropic hormone;
• phenothiazine and phenytoin derivatives;
• glucagon;
• female sex hormones;
• somatotropin;
• nicotinic acid;
• phenolphthalein;
• diuretics;
• drugs that depress the nervous system;
• synthetic androgen Danazol;
• anti-tuberculosis drug Isoniazid;
• adrenergic blocker Doxazosin.

The effect of the solution is weakened by taking sympathomimetics and iodinated tyrosine derivatives.

Combinations requiring caution

The following medications increase the risk of complications:

• endrogens and anabolics;
• a number of drugs for the treatment of cardiac and vascular disorders;
• central nervous system stimulants;
• antiarrhythmic drug Cibenzoline;
• analgesic Propoxyphene;
• angioprotector Pentoxifylline;
• cytostatic drug Trofosfamide;
• a number of antidepressants;
• sulfonamides;
• a number of medications aimed at lowering cholesterol levels;
• antibiotics of the tetracycline group;
• drugs based on somatostatin and its analogues;
• hypoglycemic agents;
• appetite regulator Fenfluramine;
• antitumor drug Ifosfamide.

Caution is required when taking medications based on salicylic acid esters, tritoqualine, cyclophosphamide, guanethidine and phentolamine.

Lithium salts can weaken or enhance the effect of the drug. Reserpine and clonidine have the same effect.

The use of beta blockers increases the risk of complications.

Alcohol compatibility

In chronic alcoholism, the level of glycemia changes. In case of diabetes mellitus, alcohol tolerance is reduced; consultation with a doctor is necessary regarding safe doses of alcoholic beverages. Glucose concentrations may drop to critical levels.

After the first use, the bottle can be stored for 4 hours, the cartridge - for 28 days after installation. During storage, exposure to light should be avoided and the temperature should not rise above +25°C.

Best before date

From the date of production, the solution is suitable for use for 2 years.

Manufacturer

The drug is manufactured by Sanofi-Aventis. The country of production can be Germany or Russia.

Active ingredient

Insulin soluble human genetically engineered

Dosage form

injection solution

Manufacturer

Sanofi-Aventis, France

Compound

Active ingredient: soluble insulin (human genetically engineered) 3.571 mg (100 IU);

Excipients: metacresol (m-cresol) - 2.7 mg, sodium dihydrogen phosphate dihydrate - 2.1 mg, glycerol 85% - 18.824 mg, sodium hydroxide (to adjust pH) - 0.576 mg, hydrochloric acid (to adjust pH) - 0.232 mg, water d/i - up to 1 ml

Pharmacological action

Hypoglycemic drug, short-acting insulin. Insuman Rapid contains insulin, identical in structure to human insulin and obtained by genetic engineering using the K12 strain of E. coli.

Insulin lowers blood glucose concentrations, promotes anabolic effects, and reduces catabolic effects. Increases the transfer of glucose into cells and the formation of glycogen in muscles and liver, improves pyruvate utilization, inhibits glycogenolysis and glyconeogenesis. Insulin increases lipogenesis in the liver and adipose tissue and inhibits lipolysis. Promotes the entry of amino acids into cells and protein synthesis, increases the flow of potassium into the cell.

Insuman Rapid is an insulin with a rapid onset and short duration of action. After subcutaneous administration, the hypoglycemic effect occurs within 30 minutes, reaches a maximum in 1-4 hours, and persists for 7-9 hours.

Indications

• diabetes mellitus requiring treatment with insulin;
• treatment of diabetic coma and ketoacidosis;
• achieving metabolic compensation in patients with diabetes mellitus during surgical interventions (before surgery, during surgery and in the postoperative period).

Contraindications

• hypoglycemia;
• hypersensitivity reactions to insulin or to any of the auxiliary components of the drug.

The drug should be used with caution in renal failure (a decrease in the need for insulin may occur due to a decrease in insulin metabolism), in elderly patients (a gradual decrease in renal function may lead to a permanent decrease in the need for insulin), in patients with liver failure (the need for insulin may decrease due to a decrease in the ability for gluconeogenesis and a decrease in insulin metabolism), in patients with severe stenosis of the coronary and cerebral arteries (hypoglycemic episodes may be of particular clinical significance, since there is an increased risk of cardiac or cerebral complications of hypoglycemia), in patients with proliferative retinopathy (especially those who have not received treatment with photocoagulation (laser therapy), since with hypoglycemia they have a risk of transient amaurosis - complete blindness), in patients with intercurrent diseases (the need for insulin often increases).

Side effects

From the cardiovascular system: frequency unknown - decreased blood pressure.

Metabolism and nutrition: often - edema; frequency unknown - sodium retention. Similar effects are possible when previously poor metabolic control is improved by using more intensive insulin therapy.

From the organ of vision: frequency unknown - transient visual disturbances (due to temporary changes in the turgor of the lenses of the eyes and their refractive index), temporary worsening of diabetic retinopathy (due to more intensive insulin therapy with a sharp improvement in glycemic control), transient amaurosis (in patients with proliferative retinopathy, especially if they are not treated with photocoagulation (laser therapy)).

From the skin and subcutaneous tissues: frequency unknown - development of lipodystrophy at the injection site and slowdown in local absorption of insulin. Constantly changing injection sites within the recommended injection area may help reduce or stop these reactions.

General disorders and disorders at the injection site: frequency unknown - redness, pain, itching, urticaria, swelling or inflammatory reaction at the injection site. Most severe reactions to insulin at the injection site usually disappear after a few days to a few weeks.

Interaction

Concomitant use with oral hypoglycemic drugs, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, propoxyphene, salicylates, amphetamine, anabolic steroids and male sex hormones, cybenzoline, cyclophosphamide, fenfluramine, guanethidine, ifosfamide, nom, phentolamine, somatostatin and its analogues, sulfonamides, tetracyclines, tritoqualine or trofosfamide may enhance the hypoglycemic effect of insulin and increase the susceptibility to the development of hypoglycemia.

Concomitant use with corticotropin, corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, estrogens and gestagens (for example, those present in COCs), phenothiazine derivatives, somatotropin, sympathomimetic agents (for example, epinephrine, salbutamol, terbutaline), thyroid hormones, barbiturates, nicotinic acid, phenolphthalein, phenytoin derivatives, doxazosin can weaken the hypoglycemic effect of insulin.

Beta-blockers, clonidine, and lithium salts can either potentiate or weaken the hypoglycemic effect of insulin.

Ethanol can potentiate or weaken the hypoglycemic effect of insulin. Drinking ethanol can cause hypoglycemia or reduce already low blood glucose levels to dangerous levels. Ethanol tolerance is reduced in patients receiving insulin. The doctor should determine the acceptable amounts of ethanol consumed.

When used simultaneously with pentamidine, hypoglycemia may develop, which can sometimes develop into hyperglycemia.

When used simultaneously with sympatholytic agents such as beta-blockers, clonidine, guanethidine and reserpine, symptoms of reflex (in response to hypoglycemia) activation of the sympathetic nervous system may be weakened or completely absent.

Overdose

Symptoms: Insulin overdose, such as taking too much insulin relative to food intake or energy expenditure, can lead to severe and sometimes prolonged and life-threatening hypoglycemia.

Treatment: mild episodes of hypoglycemia (the patient is conscious) can be stopped by taking carbohydrates orally. Adjustments to your insulin dose, food intake, and physical activity may be necessary. More severe episodes of hypoglycemia with coma, convulsions or neurological disorders can be treated with intramuscular or subcutaneous administration of glucagon or intravenous administration of a concentrated dextrose solution. In children, the amount of dextrose administered is set in proportion to the child's body weight. After an increase in blood glucose concentrations, maintenance carbohydrate intake and observation may be required. After the apparent clinical elimination of the symptoms of hypoglycemia, its re-development is possible. In cases of severe or prolonged hypoglycemia, an infusion of a less concentrated dextrose solution is recommended following a glucagon injection or dextrose injection in order to prevent the recurrence of hypoglycemia. In young children, it is necessary to carefully monitor the concentration of glucose in the blood, due to the possible development of severe hyperglycemia. Under certain conditions, it is recommended to hospitalize the patient in the intensive care unit to more closely monitor their condition and control the therapy.

Special instructions

The dose of the drug should be selected with caution in patients with pre-existing ischemic cerebral circulatory disorders and severe forms of coronary artery disease.
The need for insulin may change in the following cases: when switching to another type of insulin; with changes in diet, diarrhea, vomiting; when changing the usual volume of physical activity; for diseases of the kidneys, liver, pituitary gland, thyroid gland; when changing injection site.
The patient should be informed about the symptoms of a hypoglycemic state, the first signs of a diabetic coma and the need to inform the doctor about all changes in his condition.
Alcohol tolerance is reduced in patients receiving insulin.

Depending on the clinical picture, a diabetic takes different medications.

In situations requiring insulin treatment, hypoglycemic injections are prescribed. One of these drugs is Insuman Rapid GT.

General characteristics

Insuman Rapid is a medicine prescribed for the treatment of diabetes. Available in liquid form and used as an injection.

In medical practice it can be used with other types of insulin. Prescribed for type 1 diabetes and type 2 diabetes when glucose-lowering tablet drugs are ineffective, intolerant or contraindicated.

The hormone has a hypoglycemic effect. The medicine contains human insulin with 100% solubility and short action. The substance was obtained in the laboratory using genetic engineering.

Soluble insulin is the active ingredient of the drug. The following components were used as an additive: m-cresol, glycerol, purified water, hydrochloric acid, sodium hydroxide, sodium dihydrogen phosphate dihydrate.

Pharmacological properties

Insuman lowers blood sugar levels. Refers to drugs with a rapid and short period of activity.

The effect is expected half an hour after the injection and lasts up to 7 hours. The maximum concentration is observed in the 2nd hour after subcutaneous administration.

The active substance interacts with cell receptors, producing an insulin receptor complex. It provokes the synthesis of necessary enzymes and stimulates intracellular processes. As a result, the absorption and assimilation of glucose by the body is enhanced.

Action of insulin:

• stimulates protein synthesis;
• prevents the destruction of substances;
• inhibits glycolenolysis and glyconeogenesis;
• enhances the transport and absorption of potassium;
• improves the synthesis of fatty acids in the liver and tissues;
• slows down the breakdown of fats;
• improves the transport and absorption of amino acids.

Indications and contraindications

The medicine is prescribed in the following cases:

• DM 1 (insulin-dependent form) and DM 2;
• for the treatment of acute complications;
• to eliminate diabetic coma;
• receiving exchange compensation during preparation and after the operation.

The hormone is not prescribed in the following situations:

• renal/liver failure;
• resistance to the active substance;
• coronary/cerebral artery stenosis;
• drug intolerance;
• persons with intercurrent diseases;
• persons with proliferative retinopathy.

Important! Elderly diabetics should take it with extreme caution.

Instructions for use

Selection and adjustment of dosage is prescribed on an individual basis. The doctor determines it from glucose levels, the degree of physical activity, and the state of carbohydrate metabolism. The patient is provided with recommendations in case of changes in glucose concentration.

The daily dose of the drug based on weight is 0.5 IU/kg.

The hormone is administered intravenously, intramuscularly, subcutaneously. The most commonly used method is the subcutaneous method. The injection is given 15 minutes before meals.

With monotherapy, the frequency of drug administration is about 3 times, in some cases it can reach up to 5 times a day. The injection site changes periodically within the same zone. Changing the place (for example, from the hand to the stomach) is carried out after consultation with the doctor. For subcutaneous administration of the medicine, it is recommended to use a syringe pen.

Important! Depending on the injection site, the absorption of the substance differs.

The drug can be combined with long-acting insulin.

Video lesson on the technique of administering insulin with a syringe pen:

Dosage adjustment

The dosage of the drug may be adjusted in the following cases:

• if your lifestyle changes;
• increased sensitivity to the active substance;
• change in patient weight;
• when switching from another medication.

In the first time after switching from another substance (within 2 weeks), enhanced monitoring of glucose levels is recommended.

Switching from higher doses of other medications to this drug must be done under close medical supervision.

When switching from animal to human insulin, dosage adjustments are made.

Its reduction is required for the following category of persons:

• low sugar was previously recorded during therapy;
• taking high doses of the drug previously;
• predisposition to the formation of a hypoglycemic state.

Special instructions and patients

When pregnancy occurs, drug therapy is not stopped. The active substance does not cross the placenta.

During lactation, there are no restrictions on intake. The main point is that insulin dosing is adjusted.

To prevent hypoglycemic reactions, treatment of elderly people with the drug is carried out with caution.

Persons with impaired liver/kidney function switch to Insuman Rapid and adjust the dose under the close attention of a specialist.

The temperature of the injected solution should be 18-28ºС. Insulin is taken with caution in acute infectious diseases - dose adjustment is required here. When taking the medicine, the patient avoids drinking alcohol. It may cause hypoglycemia.

Important! Taking other medications requires special attention. Some of them can reduce or increase the effect of Insuman.

When using the medicine, the patient needs to be attentive to any changes in his condition. This is necessary for timely recognition of signs preceding hypoglycemia.

Intensive glucose monitoring is also recommended. The risks of hypoglycemia associated with the use of the drug are high in individuals with poor maintenance sugar concentrations. The patient should always carry 20 g of glucose with him.

Take with extreme caution:

• with concomitant therapy;
• when switching to another insulin;
• persons with long-term presence of diabetes;
• elderly people;
• persons with gradual development of hypoglycemia;
• with concomitant mental illnesses.

Note! When switching to Insuman, the tolerability of the medication is assessed. A small dose of medication is injected subcutaneously. At the beginning of treatment, attacks of hypoglycemia may occur.

Side effects and overdose

The following negative effects after administration are identified:

In case of an overdose, the patient's sugar may drop to a low level. For mild cases, take 15 g of glucose.

A severe form with convulsions and loss of consciousness requires the administration of glucagon (intramuscular). Additional administration of dextrose (intravenously) is possible.

After stabilization of the patient's condition, it is necessary to take a maintenance dose of carbohydrates. For some time after the symptoms of hypoglycemia have resolved, monitoring of the condition will be required, since re-occurrence is possible. In special cases, the patient is hospitalized for further observation.

Interaction with other drugs

The simultaneous use of other medications is not recommended without consulting a doctor. They can increase or decrease the effect of insulin or provoke critical conditions.

A decrease in the effect of the hormone is observed with the use of contraceptives, glucocorticosteroid hormones (progesterone, estrogen), diuretics, a number of antipsychotic drugs, adrenaline, thyroid hormones, glucagon, barbiturates.

The development of hypoglycemia can occur when taking other antidiabetic medications together. This also applies to sulfonamide antibiotics, MAO inhibitors, acetylsalicylic acid, fibrates, and testosterone.

Alcohol, together with the hormone, reduces sugar to a critical level, causing hypoglycemia. The permissible dosage is determined by the doctor. You should also be careful when taking laxatives - taking them in excess can significantly affect your sugar levels.

Pentamidine can cause different conditions - hyperglycemia and hypoglycemia. The drug may cause heart failure. Especially for people at risk.

Note! The shelf life of the solution in a syringe pen is no more than a month. The date of the first medication intake should be noted.

Identical medicines (corresponding to the release form and the presence of the active component) include: Actrapid Hm, Vosulin-R, Insuvit N, Rinsulin-R, Humodar, Farmasulin N. The listed medicines include human insulin.

Every year more and more people are at risk of developing diabetes. If it was not possible to avoid the disease, then it is necessary to take all measures to prevent the development of the disease. One of the main ways to keep the disease under control is to administer insulin. The pharmaceutical market offers a large number of drugs. One of these is the Insuman Rapid GT.

Clinical picture

What doctors say about diabetes

Doctor of Medical Sciences, Professor Aronova S. M.

I have been studying the problem of DIABETES for many years. It's scary when so many people die and even more become disabled due to diabetes.

I hasten to report good news - the Endocrinological Research Center of the Russian Academy of Medical Sciences managed to develop a medicine that completely cures diabetes mellitus. At the moment, the effectiveness of this drug is approaching 100%.

Another good news: the Ministry of Health has achieved the adoption special program, which reimburses the entire cost of the drug. In Russia and the CIS countries, diabetics to can get the remedy FOR FREE.

Find out more>>

Insuman and its mechanism of action

The drug is a solution for subcutaneous administration. Intravenous injections are allowed under appropriate monitoring conditions (hospital). It consists primarily of the hormone insulin itself, which is identical to human insulin, as well as auxiliary substances. This hormone was obtained through genetic engineering. Metacresol is used as a solvent and antiseptic. Sodium dihydrogen phosphate and glycerol exhibit laxative properties. The composition also includes hydrochloric acid. All necessary information on the medicine is available in the instructions for use.

Insuman Rapid is used for insulin-dependent diabetes mellitus and diabetic coma. Promotes metabolic compensation in people during the preoperative and postoperative periods. The action of insulin Insuman Rapid GT begins within half an hour. The effect of the drug lasts for several hours. It is produced in the forms of cartridges, vials and special disposable syringe pens. The latter have cartridges installed. It is available in pharmacies by prescription and has a shelf life of two years.

Insuman Rapid has contraindications for use in patients with hypoglycemia, as well as those who have increased sensitivity to insulin.

Let's turn to the instructions. Elderly people should use the medicine with caution and under supervision. In addition, the drug should be used with caution by persons who have:

• Kidney failure.
• Liver failure.
• Stenosis of the coronary and cerebral arteries.
• Proliferative retinopathy.
• Intercurrent diseases.
• Sodium retention in the body.

In any case, Insuman Rapid GT must be used after consultation with a doctor. Consider individual reactions to individual components. The regulations do not provide for dosing rules, so the time of administration and dose are calculated individually. The main criterion is lifestyle, how physically active a person is, and what diet he follows. It follows from this that when switching from another insulin, including that of animal origin, observation in a hospital may be required. Taking Insuman GT affects concentration and motor speed. Therefore, permission to drive a car is decided only by the attending physician.

During the action of the drug, glucose levels decrease. It promotes anabolic effects and increases sugar transport in cells. Promotes the accumulation of glycogen, slows down glycogenolysis. Accelerates the process of converting glucose and other substances into fatty acids. Amino acids enter cells faster. The medicine normalizes protein synthesis and the flow of potassium into the body tissues.

Side effects and overdose

Be careful

According to WHO, every year 2 million people die from diabetes and its complications around the world. In the absence of qualified support for the body, diabetes leads to various kinds of complications, gradually destroying the human body.

The most common complications are: diabetic gangrene, nephropathy, retinopathy, trophic ulcers, hypoglycemia, ketoacidosis. Diabetes can also lead to the development of cancer. In almost all cases, a diabetic either dies fighting a painful disease or becomes a real disabled person.

What should people with diabetes do? The Endocrinological Research Center of the Russian Academy of Medical Sciences succeeded make a remedy completely cures diabetes mellitus.

Currently, the Federal program “Healthy Nation” is underway, within the framework of which this drug is given to every resident of the Russian Federation and the CIS FOR FREE. For detailed information, see official website MINISTRY OF HEALTH.

Like any other insulin-based product, which is Insuman Rapid GT, it has its side effects:

• Hypoglycemia occurs most often as a result of insulin therapy. Especially when the dosage of the drug is violated to a large extent. Severe relapses can provoke progression of neurological symptoms. This will lead to convulsions, and in the most severe cases even to coma
• An allergy to insulin can manifest itself in the form of itching, swelling of the skin and mucous membranes, and bronchospasms. Cases of decreased blood pressure and anaphylactic shock have been recorded. If an allergic reaction occurs, urgent care is needed
• Deterioration of vision
• Redness, pain, itching, inflammation, and swelling may occur at the sites where the medication is applied.

The use of Insuman Rapid GT is necessary not only as directed by the instructions, but also in accordance with the requirements of the doctor. This will avoid the risk of side effects and overdose. The latter often leads to hypoglycemia. In its mild form, the patient is conscious. It is necessary to ingest carbohydrate-containing foods, for example, porridge, peas, lentils, and boiled potatoes. When diagnosing a severe form, glucagon should be administered intramuscularly or subcutaneously. In addition, dextrose solution can be used intravenously. In some cases, hospitalization may be required.

During pregnancy, insulin therapy should be continued. It is known that insulin does not cross the placenta. An important point is the constant monitoring of the need for the hormone, which changes periodically throughout the entire period. After birth, you can safely breastfeed your baby. Please note that in some cases a dose adjustment of the drug is required.

How to use the drug

The instructions contain rules for using the form of the medicine only of the type that you purchase. For your own use, there is no need to buy each type of medicine to choose the right one. Insuman Rapid GT is available in three forms:

Our readers write

Subject: Conquered diabetes

From: Lyudmila S ( [email protected])

To: Administration my-diabet.ru

At the age of 47, I was diagnosed with type 2 diabetes. In a few weeks I gained almost 15 kg. Constant fatigue, drowsiness, feeling of weakness, vision began to fade. When I turned 66, I was already steadily injecting myself with insulin, everything was very bad...

And here is my story

The disease continued to develop, periodic attacks began, and the ambulance literally brought me back from the other world. I always thought that this time would be the last...

Everything changed when my daughter gave me an article to read on the Internet. You can’t imagine how grateful I am to her for this. This article helped me completely get rid of diabetes, a supposedly incurable disease. Over the last 2 years I have started to move more, in the spring and summer I go to the dacha every day, my husband and I lead an active lifestyle and travel a lot. Everyone is surprised how I manage to do everything, where so much strength and energy comes from, they still can’t believe that I’m 66 years old.

Who wants to live a long, energetic life and forget about this terrible disease forever, take 5 minutes and read this article.

Go to article>>>

• The bottle is made of transparent glass. Has a volume of 5 ml. When using the bottle, remove the cap. Next, draw a volume of air into the syringe that is equal to the dose of insulin. Then insert the syringe into the vial (without touching the liquid) and invert it. Dial the required insulin dosage. Before use, release the air from the syringe. Gather a fold of skin at the injection site and slowly inject the medicine. When finished, slowly remove the syringe.
• The cartridge is made of colorless glass and has a volume of 3 ml. Using Insuman Rapid GT in cartridges will not cause any difficulties. Before doing this, keep it at room temperature for a couple of hours. It is unacceptable to have air bubbles in the cartridge; if there are any, remove them immediately. Then install it in the syringe pen and inject
• The most convenient form is disposable syringe pens. It is a 3 ml transparent glass cartridge, which is built into a syringe pen. This form is one-time only. Carefully apply the measures to prevent infections that are indicated in the instructions. To use, attach the needle and inject.

Inspect bottles and cartridges carefully. The liquid should be transparent, without impurities. The use of syringes with damaged elements is not permissible. Insuman GT injection should be given 20 minutes before meals. Intramuscular use is allowed. Don't forget to change the injection site. Changing areas (from thigh to abdomen) is permissible after doctor's approval. The same applies to the use of the drug with other medications, as well as with alcohol. You can always find complete information about using Insuman Rapid insulin in the instructions.

We conducted an investigation, studied a bunch of materials and, most importantly, tested most of the methods and medications for diabetes. The verdict is:

If all drugs were given, it was only a temporary result; as soon as the use was stopped, the disease sharply intensified.

The only drug that has given significant results is Difort.

At the moment, this is the only drug that can completely cure diabetes. Difort showed a particularly strong effect in the early stages of the development of diabetes mellitus.

We made a request to the Ministry of Health:

And for readers of our site there is now an opportunity
receive Difort FOR FREE!

Attention! Cases of sales of counterfeit drug Difort have become more frequent.
By placing an order using the links above, you are guaranteed to receive a quality product from the official manufacturer. In addition, when ordering from official website, you receive a money-back guarantee (including transportation costs) if the drug does not have a therapeutic effect.